



US 20210253639A1

(19) **United States**(12) **Patent Application Publication**  
Wang et al.(10) **Pub. No.: US 2021/0253639 A1**(43) **Pub. Date: Aug. 19, 2021**(54) **HETERODIMERIC PEPTIDE REAGENTS  
AND METHODS**(71) Applicant: **REGENTS OF THE UNIVERSITY  
OF MICHIGAN**, Ann Arbor, MI (US)(72) Inventors: **Thomas D. Wang**, Ann Arbor, MI  
(US); **Jing Chen**, Ann Arbor, MI (US)(21) Appl. No.: **17/054,900**(22) PCT Filed: **May 16, 2019**(86) PCT No.: **PCT/US19/32584**

§ 371 (c)(1),

(2) Date: **Nov. 12, 2020****Related U.S. Application Data**(60) Provisional application No. 62/672,109, filed on May  
16, 2018.**Publication Classification**(51) **Int. Cl.****C07K 7/08** (2006.01)**A61K 49/00** (2006.01)(52) **U.S. Cl.****CPC** ..... **C07K 7/08** (2013.01); **A61K 49/0032**  
(2013.01); **A61K 49/0056** (2013.01)

(57)

**ABSTRACT**

The disclosure is directed to heterodimeric peptide reagents that specifically bind epidermal growth factor receptor (EGFR) and epidermal receptor growth factor 2 (ErbB2), as well as methods for detecting, targeting, diagnosing and/or treating diseases of the esophagus, including esophageal carcinoma, esophageal adenocarcinoma (EAC), high grade dysplasia (HGD) of the esophagus, and Barrett's neoplasia in a patient using the heterodimeric peptide reagents.

**Specification includes a Sequence Listing.**